The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Chi Van Dang as editor-in-chief of AACR journal Cancer Research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Chi Van Dang was named editor-in-chief of Cancer Research, a journal published by the American Association for Cancer Research.

Dang is the scientific director of the Ludwig Institute for Cancer Research, an international, not-for-profit organization of distinguished scientists dedicated to preventing and controlling cancer. He is also a professor in the molecular and cellular oncogenesis program at the Wistar Institute.

Dang’s lab was the first to report a link between an oncogene and altered cancer cell metabolism through the discovery that the oncogenic transcription factor MYC plays a pivotal role in the re-programming of fuel utilization in cancer cells, making cancers addicted to certain fuel sources. Research in the Dang laboratory currently focuses on exploiting metabolic vulnerabilities of cancer cells for therapeutic benefit.

Dang is the chair of the National Cancer Institute’s Board of Scientific Advisors, a member of the Blue-Ribbon Panel of former Vice President Joe Biden’s National Cancer Moonshot Initiative, a fellow of the American Academy of Arts and Sciences, and a member of the National Academy of Medicine.

Table of Contents

YOU MAY BE INTERESTED IN

Podcast

“There is no safe harbor:” FY26 funding bill collapses after ICE shooting of Alex Pretti

In last week’s issue of The Cancer Letter, Jacquelyn Cobb, associate editor, wrote a story about the then-promising legislative package that was passed by the U.S. House of Representatives Jan. 22. At the time, the package was expected to pass in the Senate, provide funding for the federal government through fiscal year 2026, and prevent a government shutdown that looms Jan. 30. 
Clinical

Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

A story is told that after first obtaining approval for marketing Premarin in 1942, Wyeth Laboratories didn’t lock up the secret recipe for making the hormonal drug in a company safe, to be guarded by patent lawyers.
By Claire Marie Porter
Capitol Hill

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

The U.S. House of Representatives Jan. 22 passed a three-bill minibus package that is expected to be the grand finale of the drama of the fiscal year 2026 appropriations process. The package, which funds the HHS as well as the departments of Defense, Transportation, Housing and Urban Development, Labor, and Education, gives NIH and NCI modest raises over FY25, and nullifies several  aggressive cuts the White House had proposed for NIH.
By Jacquelyn Cobb
Guest Editorial

Blood Cancer United: A new name at the right moment

This past summer, the organization I lead, formerly known as The Leukemia & Lymphoma Society, announced our new name: Blood Cancer United. It reflects our ongoing commitment to the entire blood cancer community—patients, families, caregivers, researchers, healthcare professionals, and partners—and our work to advance progress for those impacted by all types of blood cancer. 
By E. Anders Kolb
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account